个性化文献订阅>期刊> Transplantation
 

Rituximab and Intravenous Immunoglobulin Treatment of Chronic Antibody-Mediated Kidney Allograft Rejection

  作者 Fehr, T; Rusi, B; Fischer, A; Hopfer, H; Wuthrich, RP; Gaspert, A  
  选自 期刊  Transplantation;  卷期  2009年87-12;  页码  1837-1841  
  关联知识点  
 

[摘要]Kidney transplant rejections are classified into T-cell-mediated and antibody-mediated rejections (AMR). C4d staining on allograft biopsies and solid-phase assays to measure donor-specific alloantibodies have helped to precisely define the latter. Although for acute AMRs, therapy mainly relies on plasmapheresis or immunoadsorption, 110 studies for treatment of chronic AMR are available. Here, we report on four kidney allograft recipients suffering from chronic AMR I to 27 years posttransplant, who were treated with a combination of rituximab and intravenous immunoglobulin (IVIG). Rituximab/IVIG improved kidney allograft function in all four patients, whereas donor-specific antibodies were reduced in 2 of 4 patients. However, in one patient an acute rejection episode occurred 12 months after this treatment, and another patient had severe, possibly rituximab-associated lung toxicity. Thus, rituximab/IVIG may be a useful strategy for the treatment of chronic AMR, but further randomized multicenter studies are necessary to establish its efficacy and safety profile.

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内